NASDAQ:NK
Delisted
NantKwest Stock News
$6.55
+0 (+0%)
At Close: Aug 17, 2022
ImmunityBio and NantKwest Complete Merger
04:15pm, Tuesday, 09'th Mar 2021
CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger.
NK Stock Price Increases Over 15% Pre-Market: Why It Happened
05:45am, Tuesday, 09'th Mar 2021
The stock price of Nantkwest Inc (NASDAQ: NK) increased by over 15% pre-market. This is why it happened.
Stockholders of NantKwest Approve Merger With ImmunityBio
04:30pm, Monday, 08'th Mar 2021
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that leading independent proxy advisory firms Insti
NK Stock Price Increases Over 12% Pre-Market: Why It Happened
09:18am, Friday, 12'th Feb 2021
The stock price of Nantkwest Inc (NASDAQ: NK) is trading at over 12% pre-market as of 9:06 AM ET. This is why it happened.
NantKwest/ImmunityBio's COVID-19 Vaccine Candidate To Be Tested For Oral And Sublingual Route Of Administration
05:25am, Friday, 12'th Feb 2021
The FDA has signed off the expansion of Phase 1 testing of a COVID-19 vaccine candidate, developed by NantKwest Inc's (NASDAQ: NK) merger partner, ImmunityBio Inc, to include sublingual boosts
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, tod
RM LAW Announces Investigation of NantKwest, Inc.
02:17pm, Thursday, 21'st Jan 2021
BERWYN, Pa., Jan. 21, 2021 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) concerning possi
NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating potential securities violations and breach of fiduciary duty against ce
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurod
NantKwest: Taking A Deeper Dive Into Their COVID-19 Vaccine Efforts As Deaths Spike And New Variants Evolve
04:47am, Friday, 15'th Jan 2021
NantKwest and ImmunityBio announced they are preparing to merge to create a juggernaut immunotherapy and cell therapy company. Now, NantKwest investors will have ownership of ImmunityBio's impressive
NantKwest Reports Positive Interim Data In Pancreatic Cancer Trials, Stock Soars
06:44am, Thursday, 14'th Jan 2021
Clinical-stage immunotherapy company Nantkwest Inc (NASDAQ: NK) reports positive interim data on survival rates in the Metastatic Pancreatic Cancer QUILT 88 trial on Wednesday. What Happened: Nan
NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
06:01pm, Wednesday, 13'th Jan 2021
EL SEGUNDO & CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, Inc., a privately-held immunotherapy
Here's a Cancer-Killing Stock to Buy for 2021
07:18am, Wednesday, 30'th Dec 2020
"Natural killer" (or NK) cancer therapies are hot right now. Here are two stocks that are early leaders in the field -- one is a buy, and the other one is not.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of NantKwest, Inc. (NASDAQ:NK) and ImmunityBio is fair to NantKwest shareholders. Un
